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Crohn’s disease
Daniel C Baumgart, William J Sandborn
Crohn’s disease is a relapsing systemic inﬂ ammatory disease, mainly aﬀ ecting the gastrointestinal tract with 
extraintestinal manifestations and associated immune disorders. Genome wide association studies identiﬁ ed 
susceptibility loci that—triggered by environmental factors—result in a disturbed innate (ie, disturbed intestinal 
barrier, Paneth cell dysfunction, endoplasmic reticulum stress, defective unfolded protein response and autophagy, 
impaired recognition of microbes by pattern recognition receptors, such as nucleotide binding domain and Toll 
like receptors on dendritic cells and macrophages) and adaptive (ie, imbalance of eﬀ ector and regulatory T cells 
and cytokines, migration and retention of leukocytes) immune response towards a diminished diversity of 
commensal microbiota. We discuss the epidemiology, immunobiology, amd natural history of Crohn’s disease; 
describe new treatment goals and risk stratiﬁ cation of patients; and provide an evidence based rational approach 
to diagnosis (ie, work-up algorithm, new imaging methods [ie, enhanced endoscopy, ultrasound, MRI and CT] and 
biomarkers), management, evolving therapeutic targets (ie, integrins, chemokine receptors, cell-based and stem-
cell-based therapies), prevention, and surveillance.
Introduction
Crohn’s disease and ulcerative colitis are the two main 
components of inﬂ ammatory bowel disease.1 Crohn’s 
disease is a relapsing inﬂ ammatory disease, mainly 
aﬀ ecting the gastrointestinal tract, and frequently 
presents with abdominal pain, fever, and clinical signs of 
bowel obstruction or diarrhoea with passage of blood or 
mucus, or both. Because its incidence and prevalence are 
rising (appendix p 1) in all ethnic groups and because of 
the systemic nature of the illness, Crohn’s disease 
concerns an increasingly diverse group of clinicians.
Causes and pathophysiology
Genetics
Familial aggregation has been known for more than 
70 years and large concordance studies in twins in 
northern Europe were early indicators of a genetic 
component in Crohn’s disease. These data have been 
conﬁ rmed in other countries. A German nationwide 
study2 showed that 35% of monozygotic pairs, but only 
3% of dizygotic pairs, were concordant for the disorder. In 
70% of discordant monozygotic pairs the ﬁ rst-born had 
inﬂ ammatory bowel disease.2 Substantial phenotypic 
(location, behaviour, and age at diagnosis) concordance 
exists, both at diagnosis and longitudinally, in mono-
zygotic twins.3 Familial aggregation is conﬁ rmed.4 
Moreover, prevalence in Ashkenazi Jews is higher than in 
any other ethnic group and Jewish descent is an 
independent risk factor for the disorder. Genetic 
anticipation—ie, earlier disease onset in the oﬀ spring of 
parents with the disorder—has been conﬁ rmed.5
Genome wide association studies and computerised 
(in silico) meta-analyses have identiﬁ ed and conﬁ rmed 
71 susceptibility loci for Crohn’s disease on 17 chromo-
somes so far (appendix pp 2–3).6 The identiﬁ cation of 
susceptibility loci has enhanced our understanding of the 
causes of the disorder by providing important clues about 
crucial and disturbed pathways of the intestinal immune 
system. Appreciation of the role of the innate immune 
response in Crohn’s disease resulted from the discovery 
of relevant susceptibility loci in genetic research. Familial 
aggregation with occurrence of ulcerative colitis in one 
family explains why 17 of the loci that relate to Crohn’s 
disease are shared within the 47 loci identiﬁ ed for 
ulcerative colitis.7
Genome wide association studies (appendix pp 2–3) 
also link inﬂ ammatory extraintestinal symptoms8 (ie, 
ankylosing spondylitis, non-drug induced osteoporosis) 
and associated autoimmune diseases9 (ie, asthma, 
multiple sclerosis, type 1 diabetes, autoimmune thyroid 
disease, and coeliac disease) known from epidemiological 
studies on a molecular level with shared susceptibility 
loci and can explain ethnic diﬀ erences10 in the distribution 
of these associated diseases (ﬁ gure 1). However, although 
enhanced statistical models and increasing sample sizes 
from consortia will double the number of susceptibility 
loci identiﬁ ed in the future, this component still explains 
only a little more than 20% of the heritability of Crohn’s 
disease, which together with the relatively low con-
cordance rates in monozygotic twins, emphasises the 
importance of gene-gene, epigenetic, and environmental 
factors.11 Furthermore, association (statistically signiﬁ cant 
correlation) does not equal causality, which is diﬃ  cult to 
Search strategy and selection criteria
We searched PubMed, Cochrane, and Ovid databases with 
the MeSH terms “Crohn’s disease” and “inﬂ ammatory bowel 
diseases”, combined with the subheadings “epidemiology”, 
“innate and adaptive immunity”, “genetics”, “diagnosis“, 
“imaging”, “endoscopy”, “therapy”, “surveillance”, 
“prevention”, and “complications”. All relevant articles were 
critically reviewed and the most recent preferably cited. For 
basic science articles priority was given to studies involving 
human beings and for clinical research to randomised 
placebo controlled trials and meta-analyses. Relevant 
abstracts presented at major meetings were also taken into 
account for this Seminar. We focused on reports from the 
past 5 years, and the last search was done in December, 2011.
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prove.12 Identiﬁ cation of the causative gene variants in the 
many sequence polymorphisms in the regions of asso-
ciation can be very challenging, as suggested by new work 
on the IRGM1 coding region involved in autophagy.13
Environmental factors
Worldwide, north-south, east-west, and urban-rural 
gradients for incidence rates and prevalence of Crohn’s 
disease have been identiﬁ ed.14 However, a systematic 
geographic analysis,15 new studies from southern 
hemisphere countries reporting rates that are much the 
same as those in the northern hemisphere (appendix 
p 1),16 and reports of an increased incidence in rural, 
periurban regions17 argue against an independent 
geographic component. Apart from genetics, several 
alternative explanations, mostly related to lifestyle, are 
possible. The importance of environment is suggested by 
increasing incidence rates in previously less aﬀ ected 
ethnic groups such as Asians and Hispanics10 and in 
immigrants from low incidence regions moving to areas 
with a traditionally high incidence.18
Industrialisation has greatly aﬀ ected people’s lives with 
a focus on career and higher education,15 more adverse 
life events,19 less women breastfeeding,20 smaller families 
with less crowded living conditions, improved domestic 
hygiene and sanitation,21 availability and quality of (hot) 
tap water,22 adoption of a sedentary lifestyle,23 exposure to 
air pollution,24 consumption of a western diet25 loaded 
with convenience foods (often containing excessive 
amounts of sugar and polyunsaturated fats), and 
increased tobacco use. Although all of these factors 
have been implicated in Crohn’s disease, active26 and 
passive27 (even in childhood) smoking are best studied. 
Early tobacco use signiﬁ cantly increases the risk of 
developing the disorder.28 Mechanistically, apparently 
neither nicotine nor carbon monoxide are the cause.
Crohn’s disease frequently occurs after infectious 
gastroenteritis,29 has a distinct mucosal ﬂ ora (dysbiosis),30 
and increased numbers of intramucosal bacteria31 often 
featuring adhesive species32 and thus eﬀ orts to identify a 
causative infectious agent continue. The disorder 
resembles infectious granulomatous ileitis conditions 
including intestinal tuberculosis and Johne’s disease, a 
zoonosis caused by Mycobacterium avium paratuberculosis, 
which induces similar immune responses to Crohn’s 
disease.33 Mycobacteria have been identiﬁ ed in tissues and 
blood of adult34 and paediatric35 (early onset) patients with 
Crohn’s disease and they remain an important diﬀ erential 
diagnosis in endemic areas.36 Controlled trials with 
antituberculous drugs have failed.37 Myco bacteria-related 
Crohn’s disease research frequently comes from ruminant 
farming areas where alternative explanations including 
contaminated foods and drinking water38 occur. However, 
mycobacteria still stand out from all other suspected 
infectious causes since genome wide association studies 6,39 
showed shared susceptibility loci with leprosy (ie, NOD2, 
LACC1) and poly morphisms in autophagy (ie, CARD9, 
IRGM1) required for mycobacterial clearance. The 
association of Crohn’s disease with measles or other 
viruses, Listeria, or Yersinia was not conﬁ rmed. However, 
animal research suggests that viral infections—as an 
environmental factor—might convert genetic suscepti-
bility to disease outbreak.40 Results of a meta-analysis 
suggest a link to contraceptives,41 but not to measles-
mumps-rubella42 or BCG43 vaccines. Although a meta-
analysis44 conﬁ rmed a substantial risk of development of 
Crohn’s disease after appendicectomy, this ﬁ nding 
probably results from diagnostic problems in patients 
with incipient Crohn’s disease.
Immunobiology
Crohn’s disease seems to result from an impaired 
interaction of the intestinal commensal microbiota that 
is normally in a state symbiotic mutualism with the 
human host (immune system). Despite enormous 
progress in understanding the many facets of this 
ancient relation, distinction between primary inciting 
events and secondary occurrences is challenging.
Microbiota
Metagenomic research suggests that up to four major 
bacterial phyla (Bacteroidetes, Firmicutes, Actinobacteria, 
and Proteobacteria) consisting of thousands of mostly 
anaerobic species colonise the human gut with a steep, 
stomach-acid driven, proximal-distal gradient. Species 
diversity in the gut normally also varies according to 
temporal,45 individual,46,47 dietary,48 and drug induced49 
factors. However, healthy intestinal microbiota variation 
is overall stratiﬁ ed and not continuous.50 Comparative 
studies showed clustering51 and reduced diversity espe-
cially within the Firmicutes and Bacteroidetes phyla in 
patients with Crohn’s disease.31,52,53 A reduction of 
Faecalibacterium prausnitzii (a Firmicute), was associated 
with an increased risk of postoperative recurrence of ileal 
Crohn’s disease and its experimental restitution had anti-
inﬂ ammatory eﬀ ects.54 Crohn’s disease is not caused by 
diminished commensal diversity alone, but requires a 
susceptible genotype—as conﬁ rmed by research in mice 
with human-relevant susceptibility mutations.55
Intestinal barrier
The ﬁ rst line of defence of the mucosal immune system 
is a polarised single layer of epithelial cells covered by 
mucus bioﬁ lm secreted from goblet cells with inter-
spersed bacteria.31 Decreased expression of the mucin 
gene MUC1 in the inﬂ amed terminal ileum in patients 
with Crohn’s disease suggests that mucin cover becomes 
insuﬃ  cient.56 This hypothesis is supported by genome 
wide association studies6 that link MUC1, MUC19, 
and PTGER4 to the disorder.6 The paracellular route of 
ﬂ uxes between neighbouring epithelial cells is normally 
blocked by tight junctions. In Crohn’s disease this tight 
seal becomes leaky,57 possibly because of changes in the 
expression of tight-junction proteins such as claudins,58 
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resulting in increased permeability and access of luminal 
antigens to the lamina propria, which is densely 
populated with immune cells. In-vitro and animal studies 
link tight-junction proteins59–61 and permeability changes 
that are mediated by myosin light chain kinase59,62 to 
activated T cells, the prototypical Crohn’s disease cyto-
kines tumour necrosis factor (TNF) α59,62 and interferon 
γ61, and intestinal microbiota via NOD2.62 Permeability 
defects have been reported in clinically healthy ﬁ rst 
degree relatives of patients with Crohn’s disease who 
have a NOD2 mutation.6,63 Paneth cells are also highly 
specialised epithelial cells. They defend the mucosal 
barrier by excretion of antimicrobial peptide granules, 
such as α-defensins, and regulate the makeup of the 
commensal microbiota.64 Paneth cells from patients with 
Crohn’s disease carrying the 300T→A variant of the 
autophagy gene ATG16L have fewer, dysmorphic, and 
functionally impaired granules than do those with other 
variants.65 Additional evidence linking Paneth-cell 
dysfunction and ileal inﬂ ammation to polymorphisms in 
XBP1 and NOD2 comes from animals.66,67 Endoplasmic 
reticulum stress in the highly active secretory goblet and 
Paneth cells is mechanistically linked to autophagy and 
might disturb the unfolded protein response of these 
cells and induce inﬂ am mation.68
Microbial sensing, innate immunity, and autophagy
Microbe associated molecular patterns such as lipopoly-
saccharide, peptidoglycan-derived muramyl dipeptide, 
lipoteichoic acid, single and double stranded RNA and 
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Figure 1: Healthy small intestinal immune system
AP-1=activator protein 1. B=B cell. Be=B eﬀ ector cell. Breg=regulatory B cell. CD=cluster of diﬀ erentiation. CCL=C-C motif chemokine ligand. CCR=C-C motif chemokine receptor. CXCL=C-X-C motif 
chemokine ligand. CXCR=C-X-C motif chemokine receptor. DC-SIGN=dendritic cell-speciﬁ c intercellular adhesion molecule-3-grabbing non-integrin. ELAM=endothelial-leucocyte adhesion molecule. 
FoxP3=forkhead box P3. G=goblet cell. GATA=GATA binding protein. ICAM=intercellular adhesion molecule. IFN=interferon. Ig=immunoglobulin. IL=interleukin. IEL=intraepithelial lymphocytes. 
JNK=c-Jun N-terminal kinases. KK=IκB kinase. LECAM1=leukocyte endothelial cell adhesion molecule. LFA=lymphocyte function-associated antigen. M=microfold cell. MAdCAM=mucosal vascular 
addressin cell adhesion molecule. MKK=mitogen-activated protein kinase kinase. MyD88=myeloid diﬀ erentiation primary response gene 88. NKκB=nuclear factor κ B. NK=natural killer cell. 
NLR= nucleotide binding domain like receptor. NLRP=NACHT, leucine-rich repeat, and pyrine domains-containing protein. P2XR=P2X receptor. p38=p38 mitogen-activated protein kinases. 
P=paneth cell. PC=plasma cell. PECAM=platelet endothelial cell adhesion molecule. pDC=plasmamacytoid dendritic cell. RORγ=RAR-related orphan receptor γ. Smad=Sma and Mad related family. 
STAT=signal transducer and activator of transcription. T=T cell. nTreg=naturally regulatory T cells. iTreg=inducible regulatory T cells. iTR35=interleukin-35-dependent induced regulatory T cell. 
Tr=T regulatory cell. T-bet=Th1-speciﬁ c T box transcription factor. TECK=thymus-expressed chemokine. TGFβ=transforming growth factor β. Th=T helper cell. TNFα=tumour necrosis factor α. 
TLR=toll-like receptor. 
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methylated DNA (CpG), and luminal dietary compo -
nents are recognised by diﬀ erent innate immune-cell 
populations of the intraepithelial and lamina propria 
mucosal spaces through pattern recognition receptors 
such as Toll-like receptors (TLR) and nucleotide binding 
domain (NOD) like receptors (NLR). Dendritic cells 
express the widest range of pattern recognition receptors 
and interpret microbial patterns to direct other immune 
cells towards immunity or tolerance. They form trans-
epithelial dendrites that enable them to directly sample 
luminal antigens.69 Their distribution70 and phenotype70,71 
correlate with disease activity72 in Crohn’s disease, 
and increased expression of TLR273 and TLR471 and 
exaggerated lipopolysaccharide response71 have been 
reported. The dichotomic role of TLR is shown by data 
from animals in which commensal induced TLR 
signalling through MyD8874 prevents intestinal inﬂ am-
mation, whereas deletion of TLR575 drives it. The ability 
of dendritic cells to induce tolerogenic regulatory T cells 
(Treg) might be lost in Crohn’s disease.76 Cytosolic NLR 
are another major group of pattern recognition 
receptors—some have a caspase recruitment domain 
(ie, NOD1 and NOD2) and others a pyrin domain. NOD2 
polymorphisms are strongly associated with Crohn’s 
disease6 and experimental evidence links them to a 
weakened inﬂ ammatory cytokine response towards 
muramyl dipeptide77 and ineﬀ ective autophagy,78 and to 
IL10 transcription.79 Impaired autophagy80 of invasive 
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Figure 2: Intestinal immune system in Crohn’s disease 
For therapeutic targets see text and appendix p 6. AP-1=activator protein 1. B=B cell. Be=B eﬀ ector cell. Breg=regulatory B cell. CD=cluster of diﬀ erentiation. CCL=C-C motif chemokine ligand. 
CCR=C-C motif chemokine receptor. CXCL=C-X-C motif chemokine ligand. CXCR=C-X-C motif chemokine receptor. DC-SIGN=dendritic cell-speciﬁ c intercellular adhesion molecule-3-grabbing 
non-integrin. ELAM=endothelial-leucocyte adhesion molecule. FoxP3=forkhead box P3. G=goblet cell. GATA=GATA binding protein. ICAM=intercellular adhesion molecule. IFN=interferon. 
Ig=immunoglobulin. IL=interleukin. IEL=intraepithelial lymphocytes. JNK=c-Jun N-terminal kinases. KK=IκB kinase. LECAM1=leukocyte endothelial cell adhesion molecule. LFA=lymphocyte 
function-associated antigen. M=microfold cell. MAdCAM=mucosal vascular addressin cell adhesion molecule. MDP=muramyl dipeptide. MKK=mitogen-activated protein kinase kinase. MLCK=myosin 
light-chain kinase. MyD88=myeloid diﬀ erentiation primary response gene 88. NKκB=nuclear factor κ B. NLR= nucleotide binding domain like receptor. NLRP=NACHT, leucine-rich repeat, and pyrine 
domains-containing protein. NOD=nucleotide-binding oligomerisation domain. P2XR=P2X receptor. p38=p38 mitogen-activated protein kinases. P=paneth cell. PAMP=pathogen-associated 
molecular patterns. PC=plasma cell. PECAM=platelet endothelial cell adhesion molecule. pDC=plasmamacytoid dendritic cell. RORγ=RAR-related orphan receptor γ. ROS=reactive oxygen species. 
Smad=Sma and Mad related family. STAT=signal transducer and activator of transcription. T=T cell. nTreg=naturally regulatory T cells. iTR35=interleukin-35-dependent induced regulatory T cell. 
Tr=T regulatory cell. T-bet=Th1-speciﬁ c T box transcription factor. TECK=thymus-expressed chemokine. TGFβ=transforming growth factor β. Th=T helper cell. TNFα=tumour necrosis factor α. 
TLR=toll-like receptor. VCAM=vascular cell adhesion protein. 
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microbes (xenophagy) and failure to induce an 
appropriate adaptive eﬀ ector T-cell response78 in cells 
mutant for the ATG16L81 or NOD278 autophagy genes 
that are linked to Crohn’s disease underscores the 
importance of this process.
Adaptive immunity and leucocyte migration
The adaptive immune system in Crohn’s disease is now 
thought to mediate and perpetuate, but probably not 
start, intestinal inﬂ ammation. The disorder is charac-
terised by an imbalance of eﬀ ector T cells (predominantly 
T helper [Th]1 or Th17 cells defending the mucosa against 
bacteria, fungi, and against viruses through secretion of 
interferon γ, TNFα, and interleukins 17 and 22) versus 
naturally regulatory T cells (secreting interleukin 10, and 
transforming growth factor [TGF] β or interleukin 3582) 
originating from the thymus (nTreg) and inducible 
(iTreg) cells such as Tr1, Th3, and iTr35 in the mucosa.83 
These two main opposing phenotypes, Th17 and Treg, 
originate from the same precursor and their diﬀ eren-
tiation, which is controlled by the tran scription factors 
RORγT/FOXP3, is inversely regulated.84 GWAS support 
the imbalance model by linking loci that are crucially 
involved in Treg (ie, IL10, IL2RA, SMAD3) and Th1 and 
Th17 (ie, CPEB4) diﬀ erentiation to Crohn’s disease.6 
Moreover, individual homozygous IL10R gene mutations 
derange the tightly regulated cytokine-T-cell balance and 
coincide with early onset Crohn’s disease.85 Circum-
stantial evidence such as autoantibodies, lack of mucosal 
IgA, overlap with loci associated with immunoglobulin A 
deﬁ ciency in GWAS,6,86 and production of interleukin 10 
and TGFβ by regulatory B cells suggest a role for such 
cells in this disorder. Innate and adaptive leukocyte 
migration is mediated by selectins, integrins (ie, α4β7) 
and their ligands from the immunoglobulin superfamily 
(ie, ICAM-1, MAdCAM-1), ﬁ bronectin, and chemokine 
receptors (ie, c-c motif chemokine receptor 9) and 
chemokines (ie, c-c motif chemokine ligand 25). The 
rapid recruitment and inappropriate retention of leuco-
cytes is a hallmark of Crohn’s disease (ﬁ gures 1, 2).
Diagnostic approach with assessment of 
phenotype and disease activity
Crohn’s disease is a clinical diagnosis that integrates 
history and physical ﬁ ndings with objective data from 
imaging and laboratory studies, including histopathology, 
and should neither be based nor excluded on any one 
variable or result (panel 1). Important diﬀ erential non-
infectious (ie, irritable bowel syndrome or Behçet’s 
disease87) and infectious88 diagnoses (ie, Yersinia or 
enteroviruses) that mimic Crohn’s disease need to be 
considered with particular attention to endemic diseases 
such as tuberculosis (appendix p5).36,89
Once the diagnosis of Crohn’s disease is established, 
patients should be phenotyped according to the Montreal 
classiﬁ cation (ﬁ gure 3)90 and screened for extraintestinal 
manifestations8 and associated autoimmune diseases.9 An 
assessment of disease activity (appendix p 6, 7) in com-
bination with phenotype and endoscopic features helps to 
stratify patients and allows physicians to pick the best 
possible therapeutic regimen, since these factors are 
important predictors of disease course and compli cations. 
Whereas the anatomical location is mostly stable,91 
behaviour of Crohn’s disease according to the Montreal 
classiﬁ cation varies substantially during the course of the 
disease. In a population based study92 more than half of 
Panel 1: Evidence based diagnosis techniques for a patient with suspected 
Crohn’s disease
Medical history
Start of symptoms; blood or mucus, or both, in stool; cramps incontinence; nocturnal 
diarrhoea; travel and dietary history; recent intestinal infections; non-steroidal 
anti-inﬂ ammatory drug use; appendicectomy status; active or passive smoking; family 
history of Crohn’s disease or inﬂ ammatory bowel disease; recent gastroenteritis. Screen for 
extraintestinal symptoms.
Physical examination
Heart rate, blood pressure, weight, height, body-mass index, abdominal examination, 
perianal inspection for ﬁ stulas, digital-rectal examination, look for extraintestinal 
symptoms (in the eyes, skin, joints, and muscles).
Laboratory studies
Electrolytes, blood urea nitrogen, creatinine, complete blood count with diﬀ erential, 
erythrocyte sedimentation rate, liver function tests, bilirubin, transferrin, ferritin, vitamin 
B12, folic acid, urine strip. C-reactive protein, faecal calprotectin.
Microbial studies
Stool cultures. Clostridium diﬃ  cile.
Pathology and histology
At least two biopsy samples from at least ﬁ ve segments including the ileum. 
Inﬂ ammatory cell inﬁ ltrate (lymphocytes, plasma cells) with focal crypt irregularity and 
independent granulomas.
Endoscopy
Ileocolonoscopy (spared rectum, ileal inﬂ ammation, skip lesions, cobble stoning, 
ﬁ ssural and longitudinal ulcers, strictures, ﬁ stulas). Oesophagogastroduodenoscopy 
with biopsies when symptoms occur in the upper gastrointestinal tract.
Imaging studies
CT and MRI enterography or enteroclysis scanning for extraintestinal asymptoms if 
suspected (from history or physical examination). Scanning for ﬁ stulas or abscesses if 
suspected (from history or physical examination). Small bowel capsule endoscopy 
(wireless capsule endoscopy) if terminal ileum could not be intubated or when other 
imaging studies are negative. Magnetic resonance cholangiopancreatography if primary 
sclerosing cholangitis is suspected. Endoscopic retrograde cholangiopancreatography 
with balloon dilation and bile sampling for cytology patients primary sclerosing 
cholangitis and dominant strictures.
Consultation of other specialists
Surgery, rheumatology, dermatology, ophthalmomology, urology, obstetrics and 
gynaecology (when rectovaginal ﬁ stulas are suspected) if indicated in patients with 
established or suspected extraintestinal symptoms.
Evidence level and recommendation grade according to consensus guidelines of the European Crohn’s and Colitis Organization 
are available in the appendix p 4.
Seminar
www.thelancet.com   Vol 380   November 3, 2012 1595
306 patients were diagnosed between the ages of 17 and 
40 years (Montreal category A2). Crohn’s disease was 
located in the terminal ileum in 45% (L1), colon in 32% 
(L2), ileocolon in 19% (L3), and upper gastro intestinal tract 
in 4% (L4). Most patients (81%) had a non-stricturing non-
penetrating phenotype (B1), 5% a stricturing (B2) and 14% 
a penetrating (B3 or B3p) phenotype. Almost a ﬁ fth (19%) 
of patients progressed to a more aggressive phenotype at 
90 days and more than half (51%) at 20 years after initial 
diagnosis, especially when ileal and perianal involvement 
(ﬁ stulas) were present at the time of diagnosis.
Diagnostic instruments
Endoscopy
The gold standard for all patients with Crohn’s disease is a 
full ileocolonoscopy with biopsies. Chromoendoscopy 
with methylene blue dye-spray targeted biopsies results in 
improved detection of dysplasia compared with con ven-
tional random and sequential biopsy methods.93 Although 
digital alternatives such as narrow band imaging are less 
time consuming, they cannot be recommended as a 
standard technique because of increased rates of missed 
dysplasia.94 Capsule endoscopy might be more sensitive 
compared with enterography or enteroclysis combined 
with CT (CTE) and MRI (MRE) in patients without endo-
scopic or clinical sus picion of stenosis.95
CT and MRI enterography or enteroclysis
Enteroclysis is distinguished from enterography by the 
need to apply luminal contrast through an enteric tube. 
CTE oﬀ ers the highest spatial resolution and has replaced 
small bowel ﬂ uoroscopy in leading centres. It is very 
sensitive, can show inﬂ ammation missed by other tech-
niques, can detect complications such as obstruction, 
ﬁ stulas, and abscesses, and might even be cost eﬀ ective. 
Its major disadvantage is high radiation exposure, 
although sophisticated mathematical algo rithms of 
image acquisition and processing can reduce it. MRE is a 
non-radiating, non-iodine-contrast based alternative to 
CTE. With appropriate protocols it can provide movies to 
assess motility and detailed imaging of the bowel wall 
down to mucosal level. It is the preferred choice for 
repeated imaging, long-term follow-up and work-up of 
perianal ﬁ stula and abscess complications (ﬁ gure 4).96
Multiple sclerosis
Iritis, uveitis
Aphthous ulcers
Psoriasis
Pauciarticular arthritis
Osteoporosis
Urolithiasis
Nephritis, amyloidosis
Autoimmune hepatitis
Asthma
Sensorineural hearing loss
Autoimmune
thyroiditis
Primary sclerosing
cholangitis,
Autoimmune
cholangitis,
Overlap syndrome  
 
 
Pyoderma gangrenosum
Erythema nodosum
Vasculitis
Myocarditis, pericarditis
Immune thrombocytopenia
Coeliac disease
Autoimmune pancreatitis,
Type I diabetes 
Axial arthropathy
(spondylitis and sacroiliitis)  
Polyarticular
arthritis 
Montreal  L-category
Montreal  B-category
L1
Terminal ileum
B1
Without stricture
formation
non-penetrating
L2
Colon
L3
Ileocolon
L4
Upper GI tract
B3
Penetrating
B3p
Perianally penetrating
B2
Stricturing
L4+L3
Upper GI tract and
distal disease
A B
Figure 3: Phenotype of Crohn’s disease
(A) Montreal classiﬁ cation.90 Classiﬁ cation by age is A1 <16 years, A2 17–40 years, A3 >40 years. (B) Major extraintestinal manifestations8 and associated autoimmune disorders9 (blue). GI=gastrointestinal. 
p=perianal disease modiﬁ er. p is added to B1–3 when concomitant perianal disease is present. L4 describes upper GI disease and is also used as a modiﬁ er that can be added to L1–L3 when concomitant 
upper GI disease is present.
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Ultrasound (sonography)
Native and (gas or shell microbubble) contrast-enhanced 
abdominal ultrasound (ﬁ gure 4) is a readily available, 
non-invasive imaging technique with an overall sensi-
tivity and speciﬁ city that are much the same as with MRI 
and CT.96 Prospective studies have shown utility for the 
initial diagnosis, assessment of disease activity, detection 
of ﬁ stulas, stenoses and abscesses, and signiﬁ cant 
correlation with histopathology, laboratory ﬁ ndings, vali-
dated disease activity indices, and endoscopy. Trans rectal 
and endoscopic ultrasound can assist in perianal 
complications (ﬁ gure 4).
Biomarkers
X-ray based imaging procedures are an important source 
of exposure to ionising radiation and can result in high 
cumulative eﬀ ective doses. Patients with Crohn’s disease 
had a 2·5 times higher total eﬀ ective dose than did those 
with ulcerative colitis in one study.97 Eﬀ orts to follow-up 
patients with the least invasive procedures and to still 
base decisions on objective, cost-eﬀ ective variables 
drives the discovery, development, and assessment of 
biomarkers.98 The best studied follow-up biomarkers are 
C-reactive protein and the faecal granulocyte proteins 
lactoferrin and calprotectin. Several studies have 
conﬁ rmed good correlation with other laboratory tests, 
endoscopic and clinical disease activity indices, and 
possible predictive potential.
Medical management
Key points when caring for a patient with Crohn’s disease 
are listed in panel 2. According to population based data 
from 1935–2008, 50% of adult patients with Crohn’s 
disease have an intestinal complication within 20 years 
after diagnosis. Only 10% of patients have prolonged 
clinical remission. The annual incidence of admission to 
hospital is 20%. 50% of the patients require surgery within 
10 years after diagnosis and the risk of post operative 
recurrence is 44–55% after 10 years.91 Life expectancy is 
slightly reduced. Treatment of Crohn’s disease aims to 
achieve sustained clinical and endoscopic remission99 
(mucosal healing) and to interrupt the naturally pro-
gressive destructive disease course that culminates in 
intestinal failure and asso ciated compli cations. Despite an 
abun dance of instru ments (appendix p 6), techniques and 
deﬁ nitions that can objectively deﬁ ne disease modiﬁ cation 
and intestinal damage are still in evolution.100 The newly 
proposed Lémann score could help in this process 
(ﬁ gure 5).101 Young age, immediate need for cortico-
steroids, perianal disease, colonic resection, repeated 
small bowel resection, a stricturing phenotype, sub stantial 
weight loss, and speciﬁ c endoscopic lesions might predict 
a disabling disease course.102
Smoking and nutrition
Patients with Crohn’s disease should quit smoking. 
Smoking promotes a ﬁ stulising and stricturing 
A B
Panel 2: Key points when caring for a patient with 
Crohn’s disease
• Do a careful work-up considering important 
diﬀ erential diagnoses
• Establish the complete disease phenotype including 
extraintestinal symptoms
• Screen for predictors and biomarkers of a complicated 
disease course
• Individualise therapeutic guideline recommendations to 
your patient
• Consider involving an inﬂ ammatory bowel disease expert 
for optimum treatment choice
• Educate and counsel your patient about disease and 
therapy associated risks and complications
• Enrol your patient in surveillance programmes and 
follow-up the patient closely
Figure 4: Stenosis in Crohn’s disease
(A) MR enterography of Crohn’s disease restricted to the terminal ileum (Montreal category L1) with inﬂ ammatory 
stenosis. (B) Ultrasound image of an intestinal stenosis in Crohn’s disease.
Surgery
Stricture
Fistula/abscess
Stricture
DiagnosisDisease
onset
Di
ge
st
iv
e 
da
m
ag
e
Inﬂam
m
atory activity
(CDAI, CDEIS, CRP)
Early
disease
ClinicalPre-clinical
Figure 5: The Lémann score
Exemplary visualisation of the Lémann score, a new technique to score and study intestinal damage in Crohn’s 
disease. CDAI=Crohn’s disease activity index. CDEIS=Crohn’s disease of endoscopic severity. CRP=C-reactive 
protein. Adapted from Pariente and colleagues,101 by permission of Wiley.
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pheno type, aggravated disease course, and suboptimal 
re sponse to medical therapy. Unlike in children, evidence 
to support exclusive therapeutic parenteral nutrition 
or enteral nutrition (including elemental diets) is insuf-
ﬁ cient in adult patients with Crohn’s disease. However, 
nutritional deﬁ ciencies should be corrected.103
Choice of the initial drug
Choice of the initial drug from an increasingly expanding 
matrix of medications (table) is directed by phenotype, 
disease activity, comorbidities, and other individual 
characteristics of the drug and patient. In most cases a 
fast acting short-term use agent (ie, steroids or anti-TNF) 
to achieve rapid symptom relief and disease control is 
combined with thiopurines or methotrexate for long-
term maintenance. The selection should aim to balance 
eﬃ  cacy with side-eﬀ ects and long-term complications. 
For example, whereas methotrexate is poor choice for a 
woman of childbearing age or patients with pre-existing 
liver disease (eg, primary sclerosing cholangitis, auto-
immune hepatitis, autoimmune cho langitis), this drug 
could be an excellent option for a patient with Crohn’s 
disease and arthropathy, because both disorders will 
beneﬁ t from the same treatment. The initial choice 
should also incorporate the individual proﬁ le and make 
more potent compounds available to high-risk patients 
earlier and avoid inﬂ exible, step-wise escalation of drug 
classes.106 However, evidence to support a general top-
down treatment model for all patients with this disorder 
is insuﬃ  cient.
Monotherapy versus combination therapy
Pivotal trials have shown the superiority of combination 
therapies with thiopurines and TNF blockers for 
improved symptom control and mucosal healing.106,107 
This advantage needs to be balanced with the increased 
risk of infectious108,109 and malignant109,110 complications. 
Although the idea of withdrawing either thiopurines or 
TNF blockers only one (underpowered) non-inferiority 
study supports the notion of withdrawing thiopurines.111
When and how to escalate therapy
Indications for switching drug classes or agents include 
primary non-response, loss of response (mostly noted 
with biological agents because of varying degrees of 
immunogenicity and anti-drug antibodies), insuﬃ  cient 
eﬃ  cacy (ie, absence of mucosal healing99), and intolerance 
or unacceptable side-eﬀ ects. Before escalation of ther-
apies by bodyweight-based dose adjustment (steroids, 
thiopurines, and inﬂ iximab), shortening of the treat-
ment interval (inﬂ iximab, adalimumab), combination or 
switch of therapeutic strategy, disease complications 
(ie, bile acid loss after surgery or novel strictures and 
newly acquired or coexisting infection) must be ruled 
out. Bacterial and viral infections can mimic Crohn’s 
disease (appendix p 5) and escalation of immuno sup-
pression in this setting can have fatal consequences.108
Duration of therapy
Since no available treatment corrects the underlying 
genetic basis of this chronic illness, most physicians 
believe that patients need long-term treatment. 
However, experts disagree about if and when drug 
holidays should be oﬀ ered.104,103,112 Although acute 
complications such as infections can be successfully 
managed with prevention, pausing drugs, and timely 
use of antimicrobials, some experts continue to express 
concern about long-term use of thiopurines and 
biological agents, particularly if used in combination. 
Evidence to determine the ideal duration of therapy is 
scarce, since randomised controlled trials are usually 
designed to ﬁ t approval agency requirements and rarely 
provide data beyond a year. Registry studies provide 
additional data about the long-term safety of various 
medical therapies, albeit with the known limitations of 
such evidence.113
Fistulising disease
Management of ﬁ stulising Crohn’s disease (B3 or B3p) 
requires careful assessment of the ﬁ stula location, extent, 
and potential complications (ie, penetration of adjacent 
organs or abscesses). If internal ﬁ stulas and complicated 
perianal ﬁ stulas are suspected, imaging, MRI, or ultra-
sound can help to guide therapy. Whereas uncomplicated 
perianal ﬁ stulae can be managed with seton placement, 
abscesses and other complications require surgical 
intervention in addition to medical therapy, which is 
usually a combination of anti-TNF with antibiotics and 
thiopurines (table).
Surgery and postoperative care
Surgery does not cure Crohn’s disease, and should be 
used restrictively, although it should not be regarded as 
the last resort. In some situations such as localised 
symptomatic ileocaecal disease it can be considered as a 
potential alternative to medical management. Speciﬁ c 
indications for surgery include abscesses, complex 
perianal or internal ﬁ stulas that are unresponsive or 
insuﬃ  ciently responsive to medical therapy, ﬁ brostenotic 
strictures with symptoms of partial or complete bowel 
obstruction, high grade dysplasia, and cancer.114
Smoking, a penetrating phenotype (B3 or B3p), and 
previous small bowel surgery increase the likelihood of 
postoperative recurrence. So far, thiopurines115 are best 
studied in this setting, but preliminary data also exist 
for inﬂ iximab,116 and additional trials investigating the 
eﬃ  cacy of other biological agents for prevention of post-
operative recurrence are underway (table).
Management of disorders commonly associated 
with Crohn’s disease
Anaemia
Chronic anaemia can be a presenting symptom in 
Crohn’s disease and is most often not caused by intestinal 
blood loss, but by disturbed iron metabolisation from 
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chronic inﬂ ammation. Intravenous iron substitution 
combined with erythropoietin is required and eﬀ ective in 
some cases.117
Arthropathy and osteoporosis
Peripheral (pauciarticular and polyarticular arthritis) 
and axial arthropathy (spondylitis and frequently 
isolated sacroiliitis) can precede intestinal symptoms in 
Crohn’s disease. Pauciarticular arthritis (oligoarthritis) 
usually aﬀ ects less than ﬁ ve large joints (eg, ankles, 
knees, hips, wrists elbows and shoulder), correlates 
with disease activity and responds to optimising 
medications, whereas polyarticular arthritis aﬀ ects 
more than joints (mostly small joints of the hand) and 
is unrelated to disease activity. Pauciarticular and 
polyarticular arthritis respond to nonsteroidal anti-
inﬂ ammatory drugs (preferably COX II inhibitors) and 
physical therapy, and ankylosing spondylitis also 
responds to anti-TNF. Patients with Crohn’s disease are 
at risk for osteoporosis (because of steroid use, and 
diminished vitamin and mineral absorption) and 
inﬂ ammation-induced bone loss and should be 
supplemented with calcium and vitamin D while taking 
steroids or should receive a bisphosphonate before 
initiation of such treatment.118
Pyoderma gangrenosum and erythema nodosum
Pyoderma gangrenosum and erythema nodosum are 
frequently associated with Crohn’s disease and diag-
nosed on clinical grounds. Biopsies are generally not 
recommended and could induce additional eruptions 
in pyoderma because of pathergy. They need to be 
distinguished from therapy associated acneiform and 
psoriasiform skin lesions119 and opportunistic infections. 
The diagnosis and management of other extraintestinal 
manifestations8 and associated autoimmune disorders9 
(ﬁ gure 3) is discussed elsewhere.104,105
New therapeutic targets and strategies
Numerous compounds targeting various aspects (inter-
leukins 6, 10, 11, 12, 17, and 23, TNFα and interferon γ, 
CD3 and CD4 T cells, leucocyte expansion and migration, 
antigen presentation by monocytes, macrophages and 
dendritic cells, oral tolerance, epithelial cell growth, 
microbial metabolism and composition) of the inﬂ am-
matory process (ﬁ gures 1, 2) with diﬀ erent compound 
classes (monoclonal antibodies, fusion proteins, small 
molecules, recombinant growth factors and oligonu-
cleotides) have been proposed and engineered for 
Crohn’s diease and other chronic inﬂ ammatory dis-
orders. Some are in clinical development (appendix p 9). 
Most of these strategies were based on scientiﬁ c data 
and conceptual frameworks derived from in-vitro 
experiments and studies with animals, few of which 
develop a true illness that resembles human Crohn’s 
disease. Prediction at the bench of what will eventually 
work at the bedside is increasingly diﬃ  cult. Perhaps 
individual genetic and environmental proﬁ les derived 
from data from genome-wide association studies need to 
be incorporated in patient selection for future clinical 
trials. Because of space constraints we focus on three 
concepts (additional investigational compounds and 
concepts are provided in the appendix p 9).
Blockade of key cytokines
Interleukin 12 aﬀ ects pathways shared by genetically 
related (appendix pp 2–3), but phenotypically diﬀ erent 
chronic inﬂ ammatory disorders such as multiple sclerosis, 
rheumatoid arthritis, and psoriasis. The p40 antibodies 
against interleukins 12 and 23 briakinumab (Abbott 
Laboratories, IL, USA)120 and ustekinumab,121 the latter of 
which is approved for psoriasis, initially showed equivocal 
eﬀ ects in Crohn’s disease, but more recently ustekinumab 
was eﬀ ective in a phase 2b induction trial for this disorder 
and is expected to enter phase 3. Both antibodies show 
better results for remission at 4–6 months than shortly 
after diagnosis and thus could be developed as main-
tenance rather than induction agents.
Blockade of leucocyte migration, adhesion, and homing
Vedolizumab (anti-α4β7, also known as MLN-02, LDP-02, 
and MLN0002) is a humanised monoclonal IgG1 antibody 
targeting integrin α4β7. Its activity is focused on α4β7 
MAdCAM-1 binding. Because MAdCAM-1 is expressed 
almost exclusively in the gastrointestinal tract it could 
have advantages compared with anti-α4 (ie, natalizumab 
and AJM300 [Ajinomoto Pharmaceuticals,  Japan], which 
is associated with risk of progressive multifocal 
leukoencephalopathy.122 Vedolizumab for Crohn’s diease 
(and ulcerative colitis) is being assessed in phase 3 trials. 
PF-00547659 (anti-MAdCAM, Pﬁ zer, USA) is a 
monoclonal IgG2 antibody directed at MAdCAM that is 
being studied in Crohn’s disease (and ulcerative colitis). 
It aﬀ ects the same target as vedolizumab from the 
opposite direction and thus also blocks α4+β7+, but not 
β7– leucocyte adhesion to MAdCAM.123 AJM300 (anti-α4) 
is an orally active small molecule that was assessed in 
one randomised placebo controlled trial in patients with 
Crohn’s diease.124 Etrolizumab (anti-β7, also known as 
rhuMAb Beta7 and PRO145223, Genentech, CA, USA) is 
a humanised monoclonal IgG1 antibody targeting the 
integrin subunit β7.125 It blocks both α4β7 and αEβ7 integrins 
and is in phase 1 and 2 trials for ulcerative colitis 
(NCT00694980, NCT01336465, NCT01461317).
GSK-1605786A and CCX282-B (both GlaxoSmith Kline, 
UK) is an orally bioavailable small molecule that 
selectively blocks the human CCR9 receptor.126 It has 
been studied in a multicentre, double-blind, placebo 
controlled, parallel group study in patients with Crohn’s 
disease. Although the primary endpoint was not 
achieved, signiﬁ cant diﬀ erences in clinical remission 
were recorded at week 12, and eﬃ  cacy for maintenance 
of remission in patients who responded to this agent was 
shown in a placebo controlled maintenance trial.127
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Cell-based therapies
Although global blockade of key immune cells, such as 
T cells, through anti-CD3 has failed in Crohn’s 
disease,127 stem cell therapies derived from adult 
haemtopoietic,128 mesenchmal stromal,129 and adipose 
tissue130 show prom ise. The best studied idea is the 
autologous, non-myeloablative haemtopoietic stem cell 
transplantation. In the largest series so far, all 
24 patients studied went into remission. The percentage 
of clinical relapse-free survival after transplantation 
was 91% at 1 year, 63% at 2 years, 57% at 3 years, 39% at 
4 years, and 19% at 5 years. The percent ages of patients 
in remission, steroid-free, or medication-free at any 
post transplantation assessment interval more than 
5 years after transplantation has remained at or greater 
than 70%, 80%, and 60%, respectively.128 A new, multi-
centre study (ASTIC) assessing this therapy has been 
halted as of January, 2012 (NCT00297193). Autolo gous 
mesenchmal stromal stem cell transplantation was 
studied in a phase 1 trial.129 Another approach involves 
locally applied adipose stem cells. A phase 2 trial 
reported healing of complex perianal ﬁ stulas in 71% of 
24 patients who received adipose stem cells in addition 
to ﬁ brin glue.130 Stem cell based therapies attract 
criticism from some experts because autologous 
transplantation reintroduces the genetically defective 
immune cells, does not address the known genetic 
defects in various other cell types (namely epithelial 
cells) and because the conceptually potentially more 
eﬀ ective allogeneic protocol carries substantial, 
myeloablation related mortality risks. Local injection of 
adipose stem cells has been criticised because its 
mechanisms are incompletely understood.
Prevention, risk management, and surveillance
Infection and vaccination
Almost all medications for Crohn’s disease are associated 
with an increased risk of potentially life-threatening 
infections.104,108 Prevention starts with selection of 
appropriate drugs for the speciﬁ c clinical situation and 
screening for active infections before initiation of 
immunosuppressive drugs, including steroids and 
biological agents.103 Special attention should be placed on 
tuberculosis, infectious hepatitis, cytomegalovirus, or 
HIV infection, and Clostridium diﬃ  cile (appendix p 5). 
Another important aspect is ensuring an up-to-date 
immunisation status. Patients with Crohn’s disease 
should be encouraged to complete their vaccinations 
before therapy according to annually updated authority 
recommendations for people with primary and secondary 
immunodeﬁ ciencies. Patients receiving natalizumab are 
at risk to develop progressive multifocal leukoen-
cephalopathy, a serious and usually fatal CNS infection 
caused by JC polyoma virus;131 these patients need special 
neurological monitoring. Natalizumab is only approved 
for Crohn’s disease in selected jurisdictions under a 
special restrictive schedule.
Family planning
Many approved Crohn’s disease therapies are safe in the 
setting of conception and pregnancy.132,133 Couples need to 
be counselled about potential eﬀ ects of inﬂ iximab, 
adalimumab, and sulfasalazine on sperm quality and 
the potential eﬀ ect of pelvic surgery on fecundity. 
Methotrexate is contraindicated in conception and 
pregnancy. Thiopurines and approved biological agents 
(except natalizumab because of absence of data) are 
generally regarded as safe with regard to conception, 
pregnancy, and breastfeeding and should be continued. 
Antibiotics, sulfasalazine, and methotrexate are contra-
indicated during breastfeeding. Women with Crohn’s 
disease might have a higher risk of an abnormal Pap 
smear compared with healthy controls and those who 
use immunomodulators have a higher risk of an 
abnormal Pap smear associated with HPV infection and 
need close cervical cancer screening.134
Malignancy
Patients with Crohn’s disease are at risk for early 
small bowel and colorectal cancer.135,136 The risk is even 
higher with a family history of sporadic colorectal can-
cer, uncontrolled inﬂ ammation, shortened colon, and 
multiple pseudopolyps.137 If more than a third of the colon 
is aﬀ ected (L3) patients should be enrolled in a 
surveillance programme 8 years after the onset of 
symptoms. Colonoscopies should be done ideally in 
remission every 1–2 years, when normal every 1–3 years 
thereafter. After 20 years the screening frequency de faults 
to the initial schedule. Patients with primary sclerosing 
cholangitis are especially at risk for right sided colorectal 
cancer and should undergo annual screening.136,137 
Dysplasia is managed according to the algorithm 
developed by Farraye and colleagues137 (appendix p 10).
Thiopiurines110 and TNF blockers109 have been inde-
pendently associated with development of mostly B-cell 
lymphomas. The rare hepatosplenic T-cell lymphomas138 
preferably aﬀ ect males younger than 35 years and 
have a very poor prognosis. Thiopurines photosensitise 
human skin to UVA radiation. This sensitivity has been 
associated with an increased risk for non-melanoma skin 
cancer in Crohn’s disease and requires protection against 
UVA and lifelong dermatological surveillance.139
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